Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

The approval of EYLEA was granted under a Priority Review, a designation that is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.  This approval was based upon the results of two Phase 3 clinical studies.  In these studies, EYLEA dosed every eight weeks, following three initial monthly injections, was clinically equivalent to the standard of care, Lucentis® (ranibizumab injection) dosed every four weeks, as measured by the primary endpoint of maintenance of visual acuity (less than 15 letters of vision loss on an eye chart) over 52 weeks.  The most common adverse reactions (frequency of 5% or more) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.  The adverse event profile was similar to that seen with ranibizumab.

"The approval of EYLEA offers a much needed new treatment option for patients with wet AMD," said Jeffrey Heier, M.D., a clinical ophthalmologist and retinal specialist at Ophthalmic Consultants of Boston, Assistant Professor of Ophthalmology at Tufts School of Medicine, and Chair of the Steering Committee for the VIEW 1 trial.
"EYLEA offers the potential of achieving the efficacy we've come to expect from current anti-VEGF agents, but with less frequent injections and no monitoring requirements.  This may reduce the need for cos
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. ... were exposed to high levels of air pollution late in ... U.S. study suggests. Researchers found that of nearly 1,800 ... exposed to the most air pollution during pregnancy were twice ... And exposure during the third trimester, specifically, showed the strongest ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Traveling through ... the measles virus to three others within a four-hour ... spread, a new report shows. "The exposures in ... domestic rather than an international terminal, highlighting the fact ... by Jared Vega, an infectious disease specialist at the ...
(Date:12/19/2014)... Steven Reinberg HealthDay ... If you can,t balance on one leg for at least ... Japanese researchers suggest. Difficulty standing on one leg may ... which means the risk for more serious strokes is high, ... Stroke . "Individuals showing instability while standing on one ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Future” and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay ... struggle with heart failure, experts say new treatments have ... for these patients. "The present environment for heart ... that will truly remove the term ,failure, from the ...
... Hall Institute scientists have revealed new details about ... system, identifying in the process potential new therapeutic ... Jeff Babon and Professor Nick Nicola, from the ... respectively, study interactions between internal cell signalling proteins ...
... fracture easily. It is a major complication of spinal cord ... A new clinical trial conducted by University of Iowa researchers ... bone through programmed electrical stimulation of the muscle significantly slows ... The focus on quantifying the effective dose of load is ...
... -- In an effort to reduce and eventually eliminate cancer ... Cancer Center at Jefferson has established the Center ... Mitchell, M.D., FACP , a medical oncologist at Thomas ... Medical Oncology in the Department of Medical Oncology at Jefferson ...
... Reporter , THURSDAY, Feb. 16 (HealthDay News) -- A sweetener ... of arsenic, new research suggests. Researchers at Dartmouth College ... found in some infant formulas. Their report appears in the ... Arsenic is a natural element that can contaminate groundwater. As ...
... a free, non-promotional online program designed to support ... chronic pain. This study tested painACTION.com,s ability to ... with chronic migraine headaches. A total of 185 ... were more confident that they could prevent headaches ...
Cached Medicine News:Health News:Treatment Advances Improve the Odds for Heart Failure Patients 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 3Health News:Cell signaling discovery provides new hope for blood disorders 2Health News:High doses of 'load' slows loss of bone in spinal cord injury 2Health News:High doses of 'load' slows loss of bone in spinal cord injury 3Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 2Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 3Health News:Arsenic Might Be Found in Some Organic Foods: Study 2Health News:Arsenic Might Be Found in Some Organic Foods: Study 3Health News:painACTION.com improves migraine self-management and reduces migraine-related psychological distress 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: